Under one in 10 individuals eligible to benefit from obesity jabs including Wegovy have access to them, caution the WHO as it releases its first advice on the medications.
With over a billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.
According to projections, more than two billion will be obese by 2030 unless action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be managed with comprehensive and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to universal availability to the injections that can help people shift considerable body mass, explains the organization.
GLP-1 Therapy Scarcity
Despite the present most optimistic case, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of those who need them, as stated by the health organization.
The recommendation calls on governments and firms to widen access, through measures such as voluntary licensing.
A patent on the active ingredient – the primary component of the drug Wegovy – is due to expire in a number of countries in 2026.
How Weight-Loss Injections Function
These medications imitate a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so individuals reduce food intake.
Individuals typically begin shedding pounds within a few weeks of starting on the regular doses.
Studies indicates users may regain a significant portion after a year of discontinuing the treatment, because their usual hunger come back.
Being carrying excess weight elevates your chance for experiencing health problems, like diabetes, heart disease, brain attack, and certain cancers.
Obesity affects individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
